Aminoimidazopyridazines as kinase inhibitors

US11440913B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Michael E. Mertzman · New Hope, US
• Carolyn Diane Dzierba · Middletown, US
• Jason M. Guernon · Hamden, US
• Amy C. Hart · Ewing, US
• Guanglin Luo · Newtown, US
• John E. Macor · Guilford, US
• William J. Pitts · Newtown, US
• Jianliang Shi · Furlong, US
• Steven H. Spergel · Warrington, US

Key dates

• Filing date: Oct 29, 2018
• Grant date: Sep 13, 2022
• Expiry date: Feb 13, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/6561
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.